Can a Two-Drug combo outsmart resistant myeloma?

NCT ID NCT07757412

Not yet recruiting Disease control Sponsor: Odense University Hospital Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This phase II trial is testing whether combining teclistamab, an antibody that helps immune cells attack myeloma cells, with pomalidomide, a drug that slows cancer growth, can control multiple myeloma in people whose disease has returned or stopped responding after 1-3 prior treatments. The study enrolls about 50 adults with measurable disease who have already received lenalidomide and an anti-CD38 therapy. Researchers will track how long participants live without their cancer progressing, as well as the safety of the combination.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: teclistamab combined with pomalidomide
What this could lead to: If successful, this combination could offer a new treatment option for people with multiple myeloma that has returned or stopped responding to prior therapies.
What could go wrong: This is a phase II study with a small number of participants, so results may not be conclusive. The combination may cause side effects, and its effectiveness compared to standard care is not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA PROGRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA PROGRESSION

Contacts and locations

Locations

AUH

Aarhus, Denmark
Helsinki University Hospital Comprehensive Cancer Center

Helsinki, Finland
North Estonia Medical Centre

Tallinn, Estonia
OUH

Odense, Denmark
Oslo University Hospital, Oslo Myeloma Centre

Oslo, Norway
St. Olavs Hospital

Trondheim, Norway
Stavanger University Hospital

Stavanger, Norway
Tartu University Hospital

Tartu, Estonia
Vestfold Hospital

Tønsberg, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.